

Clark Patriot



'A Voice for All, an Echo for None.'

VOL. 19 NO. 23

CLARK, NEW JERSEY, THURSDAY, JUNE 6, 1985

USPS 115-760

20 CENTS

Shapiro captures township, state for Dem nod

By Patricia DiMaggio
Township Democrats followed the lead of state Democrats in selecting Essex County Executive Peter Shapiro as their party's nominee for governor in the Primary Election on Tuesday.

Campaigning on his seven-year record as executive, which includes initiating new programs, reducing the county tax rate and cutting the size of the county work force, Mr. Shapiro garnered a total of 268 votes in Clark, with his closest rival both locally and statewide, Sen. John F. Russo, totalling 223.

The state total, with 5,440 districts out of 5,761 reporting, showed 84,813 for Mr. Shapiro, 81,724 for Sen. Russo and 71,134 for Newark Mayor Kenneth Gibson with the other three Democrats trailing in the Primary.

Incumbent Republican Gov. Thomas H. Kean drew 194 township votes for his party's nod.

There were no contests for either party's nomination for two 22nd District Assembly seats.

Republican incumbents, Bob Franks and Maureen Ogden, drew 187 and 190 votes, respectively, in Clark, while the Democratic nominees, Florence Martone and John F. Tully, Jr., had 140 and 144 votes respectively.

The General Election will be in November.

In the race for Freeholder, the Democratic team of Charlotte DeFilippa, with 419, Walter E. Borlight, with 438, and Gerald W. McCann, with 415, defeated their opposition in Clark. Countywide they won easily.

Rowland Clark had 44 in Clark, Marjorie Patterson, 47; Daniel McGowan, 47; and Elie Ernest, 10.

The Republican ticket was unopposed with G. Richard Malgran, William H. Eldridge and James J. Fulcomer drawing 185, 181 and 183 township votes, respectively.

Running unopposed on the Democratic ticket for the state committee were Frederic S. Kessler with 417 votes, Fred W. Lester with 412, and John McKenna with 419 in Clark. On the female side were June S. Fischer with 420 votes, Joanne Rajoppi with 435 and Reni Erdos with 397.

Nominees for the four-year term on the Republican side were Richard P. Hatfield with 176 votes and Blanche Banasiak with 178 in the township.

There were no challenges on the local level for members of the county committees.

In the First Ward, First District, Democrats A. Charles Wilano and Lilian B. Krov drew 21 and 23 votes, respectively, while Republicans George B.

Ebbe and Grace L. Ebbe both garnered 19.

In the Second District Democrat Carmine Giordano drew 19 votes and Theresa Minnetti 15 and write-in candidate, Patricia Brandt, drew six. Republicans Charles E. Grunder, Jr. and Gloria Ann Kopp both had 11 votes.

In the Third District Democrats William J. Clancy and Patricia A. Clancy drew 12 and 30 votes, respectively. There were no Republican nominees.

In the Fourth District Democrats Jerome Goll and Ann N. Murach both totalled 24 votes, while Republicans Andrew Boytos and Dolores Boytos drew 14 votes each.

In the Second Ward the councilmanic race showed unopposed Democrat William D. Caruso, with a total of 172 votes, compared to

his unopposed Republican opponent, George W. Crater, who had 52 votes.

County Committee nominees in the Second Ward, First District were Democrats Louis Mezza (23) and Eileen Mezza (21) and Republicans Daniel R. Marshall (13) and Carol J. Roe (12).

In the Second District, Democrats Marc Kiempiety (39) and Virginia Huska (41); Republicans James A. Smith (18) and Beatrice S. Smith (17); Third District Democrats, Sanford Krasky (95) and Harriet O. Krasky (91); Republicans William A. Anderson (8) and Jean Anderson (8); Fourth District Democrats, write-in Phil Jacobson (6), Bernard R. Hayden (23), Carole Hayden (23) and write-in, Eglia Rully (6).

Republicans Nelson Kornstein (13) and Gloria M. Crater (13).

In the Third Ward, First District Democrats were Joseph A. Foerst (26) and Donna Mohyla Femia (26); Republicans were Robert G. Taylor (16) and Ruth DeLuca (15).

Second District Democrats, Thomas M. Dunn (21) and Patricia A. Dunn (21); Republicans Bernard G. Yarusavage (11) and Carene Sangutiano (9); Third District Democrats, Joseph A. Comarata (28) and Ann M. Mullen (28); Republicans John R. Schneider (10) and Evelyn Kassinger (9); Fourth District Democrats, Manuel Costa (30) and Lee Pratt (33); and Republican Pauline Yarem (11).

In the Fourth Ward the councilmanic race showed unopposed Democrat Peter M. Campana with 89 votes and unopposed Republican Brian P. Toal

with 51 votes. County Committee nominees were: Democrats in the First District, Mr. Campana (20) and Grace Inacio (19); Republicans Frank Montefusco, a write-in (11) and Rose Montefusco (7); Second District Democrat Joanne Lemenille (17); Republicans James E. Kehoe (20) and Barbara Bolnar (20); Third District Democrats William C. Hofschneider (20) and Rose M. Tomchak (22); Republicans Carmine F. Cristiani (14) and Gloria Cristiani (14); and Fourth District Democrats Vincent J. Sollitto (25) and Mary Jane Sollitto (27); and Republicans, Councilman Toal (7) and Virginia Neuhaus (7).



OFFICER OF YEAR...John Lang of Clark, center, who was named Officer of the Year by the Union County Dept. of Public Safety is congratulated by, left to right, Randolph Pisane, director of the department; Freeholder Edward J. Slomkowski, vice-chairman of the freeholder board; Louis J. Colletti, Union County Manager, and Joseph Carroll, Jr., director of the correctional services division of the department.

John Lang named Officer of Year

A Clark resident, John Lang, 55 a Union County Jail Corrections Officer at the Elizabeth facility, was named Officer of the Year by the county's department of public safety.

Mr. Lang, an 18 year veteran of the Union County Division of Correctional Services, received his award in a special presentation attended by representatives of the Union County Board of Chosen Freeholders and county and jail administration on May 10.

The Officer of the Year designation is presented annually to the line officer who has consistently demonstrated those qualities of job performance that reflect the highest stan-

Officer Lang began his career in 1966 as a court attendant with the sheriff's department transferring to the county jail in 1967 as a corrections officer.

During his 18 years of service Officer Lang has worked every post in the jail, and in 1979 he attended the National Institute of Corrections' Jail Center in Boulder, Colo. for training in inmate classification.

After completing his training in Boulder, Officer Lang was named the jail's first classification officer, a position he currently holds.

In the spring of 1980 the officer completed advanced classification training at the National Institute of Corrections' Jail Resource Center in Rockville, Md.

dards of professionalism in corrections, Mr. Colletti explained. Officer Lang's responsibilities include formulation of intake and screening procedures to assure proper placement of all new inmates in the general population.

In 1984 he travelled to the Contra Costa, Calif., county jail, a "state-of-the-art" correction facility to observe intake and classification procedures.

The officer, the holder of numerous citations, was cited in 1973 for his efforts in foiling an escape attempt by a group of inmates who had planned to use an officer as a hostage. In 1979 he was cited for outstanding performance in intercepting a quantity of narcotics that had been smuggled into the jail in an inmate's clothing.

A three-year Navy veteran of the submarine service based at New London, Conn. Officer Lang is married to the former Miss Emily Stango. They are the parents of three children, John, Lisa Ann and Robyn Lang.

Officer Lang, who has also been nominated Officer of the Year by the American Jail Managers Assn., was honored during National Corrections Officer Week, May 6 to 12, as designated by President Ronald Reagan.

"Officer Lang is not only an outstanding corrections officer, but an example to his colleagues and a pleasure to work with," said Joseph Carroll, Jr., director of correctional services for the county.

Merck backs innovative research, cost control

An unwavering commitment to innovative research, a program of cost control and market actions tuned to a complex global environment and the prospect of key new products highlighted management presentations at the annual stockholders meeting of Merck & Co., Inc., held at corporate headquarters in Rahway.

"The growth of generic drug sales has made research productivity and patent protection the keys to growth for innovative companies," said John J. Horan, chairman and chief executive officer of the health products firm.

"Rising expenditures for medical care throughout the world have made cost effectiveness as well as therapeutic efficacy the key to market acceptance of new products. Major companies in Europe and Japan have made consistent and heavy investments in pharmaceutical research and development and thus significantly intensified world-wide research competition. Major advances in basic research have created an exploding era in biotechnology which has attracted both major multinationals and many smaller entrepreneurial companies to the health field. Our environment is in every way an intensely competitive one," Mr. Horan added.

"We have restructured our research and development organization to establish ourselves firmly in the key bio-technology areas of the future, and we have brought into our organization some of the finest

scientists in the world today," he declared.

"We are now completing a planned \$400 million capital program to expand and modernize our research laboratories. This major commitment of resources for our modernization program was necessary to assure the company remains at the forefront of modern bio-medical research and a leader in the pharmaceutical industry. With this program now nearly complete, we would expect continuing but much lower levels of capital expenditures for research and development in the next five years," the chairman said.

"In addition Merck in recent years has carried out a major expansion of its field sales force in the United States. As new products are introduced over the coming years we will have the organization in place in the field to accommodate them. Today, among United States-based pharmaceutical companies we remain the market leader in the United States, in Europe and in Japan," he added.

"Since 1980 the company has invested over \$700 million to modernize production facilities around the world and to prepare for the manufacture of major new products soon to be introduced. The capital expenditures and expenditures peaked in 1981, and the program is now essentially complete. It has included substantial investment in environmental controls to ensure the health and safety of both our own employees and the surround-

ing environment." Our non-human pharmaceutical businesses are also well-positioned for the long term. The MSD-AGVET Division, stimulated by the outstanding acceptance of ivermectin, is re-asserting itself in major markets throughout the world. Our specialty-chemicals operations are now better defined, and we expect that business to show better growth and profitability following the divestment of the Calgon Carbon Corp. and Baltimore Aircraft Co.," Mr. Horan pointed out.

Looking forward to his retirement on Monday, July 1, Mr. Horan said, "I am grateful through the combined efforts of all of those associated with Merck, including the stockholders who have supported our efforts, countless millions of people throughout the world have better nutrition, have had pain eased and suffering relieved and are living longer and healthier lives."

Also addressing the stockholders were John L. Huck, president and chief operating officer, and Dr. P. Roy Vagelos, executive vice president. Merck announced effective July 1, Dr. Vagelos was elected president and chief executive officer and Mr. Huck was elected chairman.

Mr. Huck said, "Disciplined management of costs and assets has permitted the company to maintain a strong financial performance despite adverse pressures. Further, Merck has taken a very vigorous approach to the management of its markets."

After reviewing the previously announced first-quarter results, Mr. Huck said, "Looking beyond the first quarter the rate of sales and earnings growth will not accelerate significantly during the second quarter. However, a number of factors encourage us to believe over the balance of the year there will be improving sales growth and an accelerating rate of earnings growth. Not the least of these are the new product prospects Dr. Vagelos will describe and the introductions of 'Primaxin', our broad-spectrum antibiotic, and 'Vasotec', our new anti-hypertensive, in various markets around the world. Likewise, 1985 should continue to reflect the enormous potential of the ivermectins. This novel technology is putting Merck solidly back into the field of animal health."

Mr. Huck cited the company's cost management and productivity programs, and Merck's analysis of international markets, "focusing on our market potential in key areas of the world, assessing both our product strength and the market potential of Japan and other areas, we moved to fulfill that potential in a long-range strategic way," he said.

"Our initiative in Japan took place over a long period of time, with the purpose of laying the groundwork for the ultimate marketing of the new products coming from Merck's research programs," Mr. Huck added, "We fully recognize it will take still more time and effort for

this venture to meet our strategic goals, but the important steps are well under way. We are distressed by the actions of the Japanese government in imposing severe price reductions. These actions do not help us in the short run, but they do serve to place a higher value on innovative products, and it is in innovation that Merck expects to continue to make its mark in Japan as elsewhere."

"It was clear to us in some countries the politico-economic environment is such it would be futile to continue to try to function with our traditional presence. We have restructured our operations and reduced our exposure in Venezuela, Peru and Greece through agreements with local pharmaceutical companies. In India we recently reduced our ownership in our joint venture to a minority position. However, we continue to build our presence in Europe and other key regions of the world. And our exploration for opportunities in the People's Republic of China is increasing," Mr. Huck noted.

Dr. Vagelos told stockholders, "Merck now has underway the largest research and development program in the history of the company."

He listed some of the products emerging.

"Vasotec", Merck's first angiotensin converting enzyme (ACE) inhibitor, for use in hypertension and congestive heart failure, has now been registered in 16 countries.

"Its extraordinary safety and efficacy profile make it likely to become the new baseline therapy in the treatment of hypertension," according to Dr. Vagelos.

A second ACE inhibitor, lisinopril, is now in the late stages of development, he added.

"Coronary heart disease is responsible for more deaths than all forms of cancer combined. Agents which contribute effectively to the prevention of this disease will have enormous medical and commercial value. Our work with plasma cholesterol levels has focused on the inhibition of an enzyme involved in cholesterol synthesis. Our lead compound, mevlinol, has been very effective in reducing high plasma cholesterol levels in patients. A trial natriuretic factor (ANF) represents the first hormone known to be made and secreted by the heart. Although the discovery of ANF occurred only two years ago, Merck, in collaboration with academic scientists, has participated early in the characterization of this peptide in animal studies. It is the most potent known

diuretic," reported the new president.

"With antibiotics our marketing strategies must be formulated within the reality of hospital cost-containment, while our research activities must continue to be aimed at meeting medical needs with state-of-the-art products. Our ongoing accomplishments in the field of antibacterial research are well-represented by 'Primaxin', recognized as having the broadest known spectrum of antibacterial activity. It was introduced in Germany earlier this month. We expect it will be approved in several other countries, including the United States during this year," he added.

"In the field of anti-ulcer therapy, we have high expectations for famotidine, a histamine receptor antagonist developed by Mer-

ck under license from Yamamoto Pharmaceutical Co., Ltd. Also, omeprazole is being developed by Merck in the United States under our collaborative agreement with AB Astra. We expect to begin clinical trials with omeprazole in the United States soon," he noted.

Dr. Vagelos also highlighted two vaccines: 'Recombivax', Merck's recombinant hepatitis B vaccine, which is demonstrating potency and safety equivalent to the company's plasma-derived vaccine, and 'Varivax', Merck's vaccine against chicken pox, which is nearing the end of its development. In studies in over 2,000 healthy children the vaccine has been demonstrated to be highly efficacious without evidence of unacceptable adverse effects.

Papers set holiday deadlines

The offices of The Rahway News-Record and The Clark Patriot will be closed on Independence Day, Thursday, July 4. The newspaper will be mailed to homes and in stores on Wednesday, July 3. So that our staff members may enjoy the holiday ALL COPY FOR THE JULY 4 EDITIONS OF THE NEWSPAPERS MUST BE IN THE HANDS OF THE EDITOR, AT 2:00 P.M. ON JULY 3. Any copy brought in after the deadline will automatically be held for the following week's newspaper.